XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
Conclusion
XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice.
Trial registration number
Clinicaltrials.gov: NCT01606995.
Source: European Heart Journal - Category: Cardiology Authors: Camm, A. J., Amarenco, P., Haas, S., Hess, S., Kirchhof, P., Kuhls, S., van Eickels, M., Turpie, A. G. G., the XANTUS Investigators Tags: Atrial fibrillation Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Clinical Trials | Heart | Heart Attack | Ischemic Stroke | Middle East Health | Stroke | Study | Vitamins